NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.
An Iowa State University study concluded that Immunocidin Equine was effective in 52.9% of the cases enrolled (that had a known outcome) after 2-5 injections. The treatment was deemed safe, with swelling the only side effect.
learn more
Data from a study with Settle® has been published in the Journal of Equine Veterinary Science. The data show a positive effect of Settle on postpartum uterine involution in the mare, particularly with a two-dose regimen.
learn more
Data from a University of Kentucky study assessing the effect of Settle on histological involution, cell-mediated immunity of the uterus, and clinical endpoints associated with involution was presented in Germany today.
learn more
